Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Biol Psychiatry. 2013 Oct 23;75(11):873–883. doi: 10.1016/j.biopsych.2013.10.013

Figure 1.

Figure 1

Dorsal raphe infusion of the CRFr1 small molecule antagonist NBI 35965 (A–D) or 50 ng CRF (E–H) had male-specific effects on HPA responsiveness. (A, C) Time course of corticosterone response to a 15 min restraint (indicated by shaded region) in males (A) and females (C). (B, D) Area under the curve (AUC) analysis demonstrated a significant reduction of corticosterone output by NBI 35965 in males (B), but not in females (D). (E–H) Corticosterone response to infusion of 50 ng CRF infusion in males (E, F) and females (G, H). AUC analysis demonstrated that CRF enhancement of corticosterone release was specific to males (F). Data are presented as mean values ± SEM (n=8). *, P < 0.05 in comparison to ACSF.